Post-earnings recap
Reported
Wed, May 14, 2025
EPS actual
$-0.20
EPS est.
$-0.35
EPS surprise
+42.86%
1-day move
-1.52%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Centessa Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise. However, the stock fell by 1.5% in response to the lack of revenue guidance and overall uncertainty in the market. Investors may be cautious as the company continues to focus on its development pipeline without clear financial forecasts.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | +42.86% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide any revenue guidance.
We are pleased with our EPS performance despite the lack of revenue guidance.
Our focus remains on advancing our pipeline and managing expenses.